Overview

The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors

Status:
Completed

Trial end date:
2017-11-03

Target enrollment:

Participant gender:

Summary

This study is a single-arm, phase II study of sirolimus in patient with PIK3CA mutation and PIK3CA amplication Refractory solid tumors. sirolimus 1mg will be administered orally qd daily. To investigate the efficacy of sirolimus in patients with PIK3CA mutation and PIK3CA amplication Refractory solid tumors.

Phase:

N/A

Details

Lead Sponsor:

Samsung Medical Center

Treatments:

Everolimus
Sirolimus